Abellanida, Tessie A.

HRN: 17-03-41  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/08/2023
CEFUROXIME 500MG (TAB)
06/08/2023
06/15/2023
PO
500mg
BID
S/PVaginal Hysterectomy
Waiting Final Action 

Indication:  ProphylaxisEmpiric    Type of Infection:  Intra-abdominal    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: